Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization.
Hiten D PatelUshasi NahaVictor S ChenCaitlyn KoRachel YangAleksander DruckGoran RacJeffrey L EllisGopal N GuptaMichael E WoodsAlex GorbonosRobert FlaniganMarcus L QuekPublished in: Urology practice (2023)
NAC utilization increased over time with 85.7% of eligible patients with MIBC receiving NAC in recent years. Renal dysfunction, patient preference, and clinical contraindications were primary etiologies for lack of NAC. Fewer patients refused NAC in recent years leading to a potential ceiling for NAC utilization.
Keyphrases
- transcription factor
- neoadjuvant chemotherapy
- genome wide analysis
- end stage renal disease
- muscle invasive bladder cancer
- ejection fraction
- locally advanced
- newly diagnosed
- lymph node
- chronic kidney disease
- oxidative stress
- patients undergoing
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- radiation therapy
- risk assessment
- climate change
- early stage